The genome of the blood fluke Schistosoma mansoni
Matthew Berriman, Brian J Haas, Philip T LoVerde, R Alan Wilson, Gary P Dillon, Gustavo C Cerqueira, Susan T Mashiyama, Bissan Al-Lazikani, Luiza F Andrade, Peter D Ashton, Martin A Aslett, Daniella C Bartholomeu, Gaelle Blandin, Conor R Caffrey, Avril Coghlan, Richard Coulson, Tim A Day, Art Delcher, Ricardo DeMarco, Appolinaire Djikeng, Tina Eyre, John A Gamble, Elodie Ghedin, Yong Gu, Christiane Hertz-Fowler, Hirohisha Hirai, Yuriko Hirai, Robin Houston, Alasdair Ivens, David A Johnston, Daniela Lacerda, Camila D Macedo, Paul McVeigh, Zemin Ning, Guilherme Oliveira, John P Overington, Julian Parkhill, Mihaela Pertea, Raymond J Pierce, Anna V Protasio, Michael A Quail, Marie-Adèle Rajandream, Jane Rogers, Mohammed Sajid, Steven L Salzberg, Mario Stanke, Adrian R Tivey, Owen White, David L Williams, Jennifer Wortman, Wenjie Wu, Mostafa Zamanian, Adhemar Zerlotini, Claire M Fraser-Liggett, Barclay G Barrell, and Najib M El-Sayed
Nature, Jul 2009
Schistosoma mansoni is responsible for the neglected tropical
disease schistosomiasis that affects 210 million people in 76
countries. Here we present analysis of the 363 megabase nuclear
genome of the blood fluke. It encodes at least 11,809 genes, with
an unusual intron size distribution, and new families of
micro-exon genes that undergo frequent alternative splicing. As
the first sequenced flatworm, and a representative of the
Lophotrochozoa, it offers insights into early events in the
evolution of the animals, including the development of a body
pattern with bilateral symmetry, and the development of tissues
into organs. Our analysis has been informed by the need to find
new drug targets. The deficits in lipid metabolism that make
schistosomes dependent on the host are revealed, and the
identification of membrane receptors, ion channels and more than
300 proteases provide new insights into the biology of the life
cycle and new targets. Bioinformatics approaches have identified
metabolic chokepoints, and a chemogenomic screen has pinpointed
schistosome proteins for which existing drugs may be active. The
information generated provides an invaluable resource for the
research community to develop much needed new control tools for
the treatment and eradication of this important and neglected
disease.